Engineered immune cells target bone cancer in novel trial
NCT ID NCT05312411
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 19 times
Summary
This early-phase study tests a two-part treatment for osteosarcoma that has not responded to standard therapy or has returned. First, participants receive a modified version of their own immune cells (CAR T cells) that are designed to recognize a special marker. Then, they get infusions of a compound that attaches to tumor cells and flags them for destruction by the CAR T cells. The goal is to see if this approach is safe and feasible in up to 21 people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.